RxDoctor Payments Data

Janine Frank, MD

Internal Medicine · Norfolk, VANPI 1164495800

Payments from drug & device makers

$972in general payments, 2019–2025

Across 63 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$260
  • Novo Nordisk$114
  • Gilead$104
  • Mylan Specialty L.p.$81
  • Amarin Pharma, Inc.$72
  • Astellas Pharma US Inc$54
  • plus $286 from 11 others

What the payments were for

  • Food & beverage$972100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$972 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$147,651
Medicare patients
562
Services billed
1,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$130,713
EliquisApixaban113$124,345
JanuviaSitagliptin Phosphate49$68,285
XareltoRivaroxaban60$65,599
RybelsusSemaglutide21$36,514
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$34,631
MounjaroTirzepatide30$33,340
JardianceEmpagliflozin29$32,055
Janumet XrSitagliptin Phos/Metformin Hcl25$27,722
TrulicityDulaglutide19$26,243
MyrbetriqMirabegron26$23,990
FarxigaDapagliflozin Propanediol15$22,109
LinzessLinaclotide22$20,201
PremarinEstrogens, Conjugated20$9,858
SynthroidLevothyroxine Sodium107$7,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$114$167,226104 claims
MerckJanuvia, Janumet Xr$30$96,00674 claims
Lilly USA, LLCMounjaro, Trulicity$39$59,58349 claims
GSKTrelegy Ellipta$29$34,63136 claims
Boehringer IngelheimJardiance$27$32,05529 claims
AbbVieLinzess, Synthroid$14$27,692129 claims
AstraZenecaFarxiga, Symbicort$260$26,06328 claims
Astellas Pharma US IncMyrbetriq$54$23,99026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →